 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Pipeline
TH-302 Clinical Trials Currently Recruiting PatientsTH-302 is currently being evaluated in clinical studies involving different tumor types (solid and hematologic) as well as in combination with marketed anti-cancer therapies including chemotherapy and antiangiogenic therapies. The following clinical trials are currently recruiting patients. TH-302 is currently being evaluated in clinical studies involving different tumor types (solid and hematologic) as well as in combination with marketed anti-cancer therapies including chemotherapy and antiangiogenic therapies. The following clinical trials are currently recruiting patients. TH-CR-406: A Phase 3 randomized clinical trial of TH-302 in combination with doxorubicin compared with doxorubicin alone in patients with metastatic or locally advanced unresectable or metastatic soft tissue sarcoma. The primary efficacy endpoint is overall survival. Read more about this study on ClinicalTrials.gov MAESTRO: A Phase 3 randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared with gemcitabine in combination with placebo in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. The primary efficacy endpoint is overall survival. Read more about this study on ClinicalTrials.gov TH-CR-407: A Phase 1 single-center, open-label clinical trial of TH-302 in patients with advanced leukemias. Read more about this study on ClinicalTrials.gov TH-CR-408: A Phase 1/2 open-label clinical trial evaluating the safety, tolerability and preliminary efficacy of TH-302 in combination with dexamethasone with or without bortezomib in patients with relapsed/refractory multiple myeloma. Read more about this study on ClinicalTrials.gov TH-CR-410: A Phase 1 dose-escalation clinical trial evaluating the safety of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNET). Read more about this study on ClinicalTrials.gov NCT01403610: Phase 1 safety and efficacy study of TH-302 CNS penetration in recurrent high grade astrocytoma following bevacizumab. Read more about this study on ClinicalTrials.gov NCT01485042: Phase 1 dose-escalation study of pazopanib in combination with TH-302 in advanced solid tumors. . Read more about this study on ClinicalTrials.gov NCT01497444: Phase 1/2 study of sorafenib in combination with TH-302: Phase 1 in advanced renal cell carcinoma (RCC) and advanced hepatocellular carcinoma (HCC) and Phase 2 in 1st line advanced HCC. Read more about this study on ClinicalTrials.gov NCT01721941: Phase 1 dose escalation study evaluating the maximum tolerated dose of TH-302 when administered with doxorubicin via trans-arterial chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not transplant candidates and have unresectable disease. Read more about this study on ClinicalTrials.gov Learn MoreFor additional information about Threshold clinical trials, please contact the clinical trials group at 1-650-474-8222 or email us at clinicaltrials@thresholdpharm.com. Disclosure of RisksPlease note that the safety and effectiveness of this product have not yet been established. As with other anti-cancer agents, this investigational product may not benefit you and may cause side effects. These side effects could be severe or even life threatening. There may be side effects that are not known or predictable at this time, but that may occur at the time of treatment or later. You should discuss these risks with your physician or a study doctor.  |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
